Wenshi Wang

PhD

WenshiWenshi Wang,
PhD
Room EE-830a
E-mail: w.wang.2@erasmusmc.nl



Wenshi Wang studied veterinary medicine at Shandong Agricultural University, China (2006-2010). In 2010, he started his master program of preventive veterinary medicine at Graduate School of Chinese Academy of Agricultural Science (CAAS), China. During this period, he conducted research projects on the characterization of humoral immune responses upon zoonotic viral infection in Harbin Veterinary Research Institute, CAAS. From 2013, he started his PhD training at the department of Gastroenterology and Hepatology, Erasmus MC Rotterdam, the Netherlands. His PhD projects mainly focused on the development of novel anti-viral strategies for hepatic and gastrointestinal virus infections (e.g. hepatitis E virus, rotavirus and norovirus). He received Kiem Award (the best first publication written by young microbiologists) from Royal Dutch Society for Microbiology (2017) and FEMS research grant from Federation of European Microbiological Societies (2017).

Selected References

  • W. Wang, Y. Yin, L. Xu, J. Su, F. Huang, Y. Wang, P. P. C. Boor, K. Chen, W. Wang, W. Cao, X. Zhou, P. Liu, L. J. W. van der Laan, J. Kwekkeboom, M. P. Peppelenbosch, and Q. Pan.
    Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections.
    Sci Signal. 2017 Apr 25;10 (476).
  • W. Wang, L. Xu, J. Su, M. P. Peppelenbosch, and Q. Pan.
    Transcriptional Regulation of Antiviral Interferon-Stimulated Genes.
    Trends Microbiol. 2017 Jan 27 [Epub ahead of print].
  • W. Wang, L. Xu, J. H. Brandsma, Y. Wang, M. S. Hakim, X. Zhou, Y. Yin, G. M. Fuhler, L. J. van der Laan, C. J. van der Woude, D. Sprengers, H. J. Metselaar, R. Smits, R. A. Poot, M. P. Peppelenbosch, and Q. Pan.
    Convergent Transcription of Interferon-stimulated Genes by TNF-alpha and IFN-alpha Augments Antiviral Activity against HCV and HEV.
    Sci Rep. 2016 May 6; 6: 25482.
  • W. Wang, M. P. Peppelenbosch, and Q. Pan.
    Targeting Viral Polymerase for Treating Hepatitis E Infection: How Far Are We?
    Gastroenterology. 2016 Jun;150 (7) :1690.
  • W. Wang, M. S. Hakim, V. P. Nair, P. E. de Ruiter, F. Huang, D. Sprengers, L. J. Van Der Laan, M. P. Peppelenbosch, M. Surjit, and Q. Pan.
    Distinct Antiviral Potency of Sofosbuvir Against Hepatitis C and E Viruses.
    Gastroenterology. 2016 Dec;151 (6) : 1251-1253.
  • W. Wang, Y. Wang, Y. Debing, X. Zhou, Y. Yin, L. Xu, E. Herrera Carrillo, J. H. Brandsma, R. A. Poot, B. Berkhout, J. Neyts, M. P. Peppelenbosch, and Q. Pan.
    Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication.
    Antiviral Res. 2017 Apr;140: 1-12.
  • L. Xu, W. Wang, M. P. Peppelenbosch, and Q. Pan.
    Noncanonical Antiviral Mechanisms of ISGs: Dispensability of Inducible Interferons.
    Trends Immunol. 2017 Jan;38 (1) : 1-2.
  • L. Xu, W. Wang, Y. Li, X. Zhou, Y. Yin, Y. Wang, R. A. de Man, L. J. van der Laan, F. Huang, N. Kamar, M. P. Peppelenbosch, and Q. Pan.
    RIG-I Is A Key Antiviral Interferon-Stimulated Gene Against Hepatitis E Virus Dispensable Of Interferon Production.
    Hepatology. 2017 Feb 13. [Epub ahead of print]
  • N. Kamar, W. Wang, H. Dalton, Q. Pan.
    Direct-acting antiviral therapy for hepatitis E virus?
    The Lancet Gastroenterology & Hepatology. 2017 Mar;2(3): 154-155.